Medifast, Inc.
MED · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.09 | -0.04 | 0.24 | -2.01 |
| FCF Yield | 7.15% | -3.08% | 1.28% | -3.75% |
| EV / EBITDA | 79.22 | 22.09 | 34.92 | 30.28 |
| Quality | ||||
| ROIC | -1.53% | -0.40% | 0.82% | 0.20% |
| Gross Margin | 69.52% | 72.61% | 72.80% | 74.13% |
| Cash Conversion Ratio | -5.36 | -1.36 | -4.41 | -6.18 |
| Growth | ||||
| Revenue 3-Year CAGR | -29.35% | -29.53% | -29.18% | -27.77% |
| Free Cash Flow Growth | 326.03% | -352.44% | 126.05% | -194.14% |
| Safety | ||||
| Net Debt / EBITDA | -109.77 | -29.75 | -38.21 | -19.21 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 1.17 | 0.96 | 0.80 | 0.73 |
| Cash Conversion Cycle | 76.64 | -31.31 | -35.60 | 56.63 |